Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial
Authors:
Open Access
- 15 November 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-8
Abstract
Four hundred myopic children randomly received atropine 0.02% (n = 138) or 0.01% (n = 142) in both eyes once-nightly or only wore single-vision spectacles (control group) (n = 120) for 2 years. Spherical equivalent refractive error (SER), axial length (AL), pupil diameter (PD), and amplitude of accommodation (AMP) were measured every 4 months. After 2 years, the SER changes were − 0.80 (0.52) D, − 0.93 (0.59) D and − 1.33 (0.72) D and the AL changes were 0.62 (0.29) mm, 0.72 (0.31) mm and 0.88 (0.35) mm in the 0.02% and 0.01% atropine groups and control group, respectively. There were significant differences between changes in SER and AL in the three groups (all P < 0.001). The changes in SER and AL in the 2nd year were similar to the changes in the 1st year in the three groups (all P > 0.05). From baseline to 2 years, the overall decrease in AMP and increase in PD were not significantly different in the two atropine groups, whereas the AMP and PD in the control group remained stable (all P > 0.05). 0.02% atropine had a better effect on myopia control than 0.01% atropine, and its effects on PD and AMP were similar to 0.01% atropine. 0.02% or 0.01% atropine controlled myopia progression and AL elongation synchronously and had similar effects on myopia control each year.Keywords
Funding Information
- Medical Science and Technology Research Projects of Henan Province Health Commission (201602073)
- Key Research and Promotion Special Projects of Henan Provincial Science and Technology Department (201801591)
- Key School Research Projects of Henan Provincial Department of Education (19A320066)
- Health and Family Planning Science and Technology Talents Overseas Training Project of Henan Province (2018038)
This publication has 30 references indexed in Scilit:
- The Age‐Specific Prevalence of Myopia in AsiaOptometry and Vision Science, 2015
- Atropine Slows Myopia Progression More in Asian than White Children by Meta‐analysisOptometry and Vision Science, 2014
- Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%American Journal of Ophthalmology, 2014
- Maximum Atropine Dose Without Clinical Signs or SymptomsOptometry and Vision Science, 2013
- The complex interactions of retinal, optical and environmental factors in myopia aetiologyProgress in Retinal and Eye Research, 2012
- MyopiaThe Lancet, 2012
- Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)Ophthalmology, 2012
- Prevalence of myopia among Hong Kong Chinese schoolchildren: changes over two decadesOphthalmic and Physiological Optics, 2011
- Age‐related development of a refractive index plateau in the human lens: evidence for a distinct nucleusClinical and Experimental Optometry, 2008
- The Cycloplegic Effects of Cyclopentolate and Tropicamide on Myopic ChildrenJournal of Ocular Pharmacology and Therapeutics, 1998